688513.SH
Chengdu Easton Biopharmaceuticals Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 41.84
+2.55%Year over year
Reported trailing growth
- Revenue
- +0.9%
- EBITDA
- —
- EBIT
- +27.9%
- EPS
- +22.9%
- Free cash flow
- +45.1%
- Operating cash flow
- +29.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.4%
- EBITDA
- +8.5%
- EBIT
- +6.5%
- Net income
- +4.8%
- EPS
- -7.4%
- Free cash flow
- +33.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026